Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 109 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Orbital Diseases Clear all
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT07018323
View directory record Official record
Conditions
Graves' Disease
Interventions
IMVT-1402, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
33
States / cities
Tucson, Arizona • Concord, California • Aurora, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)

NCT02230761
View directory record Official record
Conditions
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Interventions
XOPH5 Ointment, Placebo
Drug
Lead sponsor
Topokine Therapeutics, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

NCT01868997
View directory record Official record
Conditions
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Interventions
teprotumumab, normal saline
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 3 Interventional

A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT07155668
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
VRDN-003, Autoinjector
Drug · Device
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Inglewood, California • Cape Coral, Florida • Kissimmee, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the FreedomFlow™ Orbital Atherectomy System to Treat Peripheral Artery Disease

NCT03635190
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Orbital Circumferential Atherectomy
Device
Lead sponsor
Cardio Flow, Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Altamonte Springs, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 4, 2026, 1:02 AM EDT
Enrolling by invitation No phase listed Observational

Multi-Institutional IMPACT Validation

NCT06850857
View directory record Official record
Conditions
Facial Injuries, Mandible Fracture, Le Fort, Zygomaticomaxillary Complex Fracture, Nasal Fracture, Orbital Fractures, Zygoma Fracture, Orbital Floor Fracture, Facial Laceration
Interventions
IMPACT-G Module, IMPACT-N Module, IMPACT-O Module, IMPACT-J Module, 15D Control Survey
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Sacramento, California • San Francisco, California • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 4, 2026, 1:02 AM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

NCT03108456
View directory record Official record
Conditions
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
Interventions
Orbital Atherectomy, Balloon
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
104
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 4, 2026, 1:02 AM EDT
Recruiting Phase 4 Interventional

Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

NCT06982105
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus, Osteomyelitis Acute, Septic Arthritis, Orbital Cellulitis, Facial Cellulitis, Mastoiditis, Cervical Adenitis, Retropharyngeal Abscess, Peritonsillar Abscess
Interventions
Trimethoprim Sulfamethoxazole
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Completed No phase listed Observational

Computer Modeling With Reconstruction of Maxillofacial Skeleton

NCT00583856
View directory record Official record
Conditions
Maxillofacial Injury
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
11 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2010 · Synced Oct 4, 2026, 1:02 AM EDT
Completed No phase listed Observational Results available

Coronary Flow Reserve Following Orbital Atherectomy

NCT02339545
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Orbital Atherectomy plus Stenting
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chandler, Arizona • Coon Rapids, Minnesota • Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 4, 2026, 1:02 AM EDT
Recruiting Phase 3 Interventional

Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

NCT07753603
View directory record Official record
Conditions
Thyroid Eye Disease, TED, Graves Orbitopathy
Interventions
linsitinib, Placebo
Drug
Lead sponsor
Sling Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

NCT04583735
View directory record Official record
Conditions
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
Interventions
TEPEZZA, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Not applicable Interventional Results available

Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma

NCT00387023
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Lymphoma
Interventions
Rituximab, Zevalin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 4, 2026, 1:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reliability of Hertel Exophthalmometer Measurements

NCT01691183
View directory record Official record
Conditions
Standardization of Hertel Measurements
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 4, 2026, 1:02 AM EDT
Terminated Phase 3 Interventional Results available

Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?

NCT04080505
View directory record Official record
Conditions
Graves Disease
Interventions
SSKI- Potassium Iodide
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 4, 2026, 1:02 AM EDT
Terminated Phase 4 Interventional

Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease

NCT01738243
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Hyaluronic Acid Gel injection, Saline injection
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Not applicable Interventional Results available

Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in PCI

NCT03021577
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Orbital Atherectomy System (OAS), Rotablator Rotational Atherectomy System, Magnetic Resonance Imaging (MRI)
Device · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation

NCT00415506
View directory record Official record
Conditions
Scleritis, Orbital Disease
Interventions
Rituximab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 4, 2026, 1:02 AM EDT
Completed Phase 1 Interventional

A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease

NCT06389578
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Miami, Florida • St Louis, Missouri • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 4, 2026, 1:02 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

NCT07570316
View directory record Official record
Conditions
Graves' Disease, Graves Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
21
States / cities
Orange, California • Pasadena, California • Fleming Island, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 4, 2026, 1:02 AM EDT
Recruiting Not applicable Interventional

Telehealth Music Therapy for Adults With Endocrine Disorder and Depression

NCT07413874
View directory record Official record
Conditions
Type 1 Diabetes, Hashimoto Disease, Graves Disease, Addison Disease, Autoimmune Polyglandular Syndrome Type III, Depression, Endocrine System Diseases
Interventions
Telehealth Resource Oriented Music Therapy
Behavioral
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 4, 2026, 1:02 AM EDT
Terminated No phase listed Observational

B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease

NCT02316691
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 4, 2026, 1:02 AM EDT
Terminated Phase 3 Interventional

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

NCT06307613
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 4, 2026, 1:02 AM EDT